Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
This study is a phase I, dose escalation and dose expansion study of QLS1103, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS1103 in subjects with advanced solid tumors.
Advanced Solid Tumor
DRUG: QLS1103
Maximum tolerated dose (MTD), 21 Days (first cycle)|Recommended dose for phase II (RP2D), Up to 24 approximately months|Adverse events(AEs) / Serious adverse events(SAEs), Up to 24 approximately months
Maximum observed plasma concentration (Cmax) of QLS1103, Up to approximately 2 years|Time of maximum observed plasma concentration (Tmax) of QLS1103, Up to approximately 2 years|Area under the plasma concentration-time curve (AUC) of QLS1103, Up to approximately 2 years|Objective response rate (ORR), Up to approximately 2 years|Disease control rate (DCR), Up to approximately 2 years|Duration of response (DOR), Up to approximately 2 years|Progression free survival (PFS), Up to approximately 2 years
This study is a phase I, dose escalation and dose expansion study of QLS1103, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS1103 in subjects with advanced solid tumors.